Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.
The FDA approved a wearable tumor-treating fields (TTFields) device (Optune Lua) for concurrent use with a PD-1/PD-L1 ...
The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell ...
Novocure announced on Tuesday that the FDA treated its Optune Lua wearable device for treating metastatic non-small cell lung ...
Optune Lua received FDA approval based on data from the pivotal LUNAR trial which demonstrated significant median OS ...
Novocure Ltd (NVCR) is up more than +11% after the US FDA approved the company’s Optune Lua to treat metastatic non-small cell lung cancer in adults who have progressed on or after a platinum-based ...
Novocure GmbH secured U.S. FDA approval for Optune Lua, a wearable device that delivers alternating electric fields or tumor treating fields that kill cancer cells. Indicated for use with PD-1/PD-L1 ...
Investor's Business Daily on MSN3d
Novocure Withdraws Massive Gain On FDA Approval. Why It Could Struggle To Gain Traction.Novocure stock advanced, but pulled back from massive gains after the FDA signed off on its cancer treatment device.
Leerink Partners analyst Jonathan Chang maintained a Buy rating on NovoCure (NVCR – Research Report) yesterday and set a price target of ...
Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 ...
Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...
Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback